Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Grants.gov RFA-CA-27-002 · HHS-NIH11
| Funder | National Institutes of Health |
|---|---|
| Status | open |
| Opens | 03 Jun 2026 |
| Deadline | 10 Nov 2026 — 11 days |
| Action | posted |
| Official page | https://www.grants.gov/search-results-detail/360534… |
| Last checked | 2026-10-30 06:02:42+00:00 |
The scope text was read and no clause in it rules a field out. That is not a guarantee — read the call before you commit to it.
You are reading one call. 1,058 are open right now.
A search matches words. It cannot know what your institution works on. Give the name and every open call is ranked against it — this one included.
This call page is free · no account · the report arrives by emailScope
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
Get told when something changes
Most institutions find out about a call with three weeks left. We write when something opens, moves or closes that fits what you work on, with the deadline, the fit and the funder's own exclusion clauses quoted. Nothing in a quiet week. Free, and one click to leave.
Starting from the programme you are reading: HHS-NIH11 — change it below if you like.
Leave the second box empty and you get whatever opened or changed recently, closing soonest. Fill it in and it ranks against your words instead: that is the difference between a list and a shortlist.
Scientific Network Management will send you the current list for these terms, and after that only what changes: a call that opens, a deadline that shifts, a clause that rules you out. Nothing is sent when nothing has moved. One click to stop, in every message.
One confirmation email and nothing else until you click it. No tracking pixels, no sharing, one click to unsubscribe.
Of every 100 Horizon Europe proposals
A funding strategy reads your institution's own published record against the calls that are open, and says in writing which are worth the year and which to decline, with the reason for each.
Scientific Network Management, the grant-writing practice behind this radar: 13 years of EU-funded research projects, and a founder who has served as Key Expert and Team Leader on two EU-funded technical assistance contracts establishing biotechnology centres in Türkiye.
SNM also does
No obligation, and nothing here is conditional on using us: searching the calls stays free and asks for nothing either way.